Materias dentro de su búsqueda.
Mostrando 221 - 240 Resultados de 110,380 Para Buscar '"Lu'an"', tiempo de consulta: 0.89s Limitar resultados
  1. 221
    “…A new therapeutic radiopharmaceutical for bone metastasis is (177)Lu-DOTA-zoledronic acid ((177)Lu-DOTA-ZOL). In this study, the safety and dosimetry of a single therapeutic dose of (177)Lu-DOTA-ZOL were evaluated on the basis of a series of SPECT/CT images and blood samples. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases
  2. 222
    “…LuAG:Ce (Lu(3)Al(5)O(12):Ce) is one of the most important color converters in white lighting industry. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Ultrasonic Spray Pyrolysis Synthesis and Photoluminescence of LuAG:Ce Thin Films
  3. 223
    “…Prostate Specific Membrane Antigen (PSMA) is a highly relevant target in nuclear medicine due to its overexpression in prostate cancer. The (68)Ga/(177)Lu-PSMA-1 combination is a theranostic agent for the detection and treatment of tumors overexpressing the PSMA target. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Development and Validation of Analytical Methods for Radiochemical Purity of (177)Lu-PSMA-1
  4. 224
    “…SIMPLE SUMMARY: [(177)Lu]oxodotreotide (Lutathera(®)) was approved by the European Medical Agency in 2017 and the Food and Drug Administration in 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors as the first radiopharmaceutical for peptide receptor radionuclide therapy (PRRT). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Amino Acid Solutions for (177)Lu-Oxodotreotide Premedication: A Tolerance Study
  5. 225
    “…We describe the first case report of use of Lu-177 hydroxylapatite particulates in a 35-year-old female patient who was presented with elbow joint synovitis due to rheumatoid arthritis.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Radiosynovectomy of the elbow joint synovitis in rheumatoid arthritis treated with Lutetium - 177 labeled hydroxylapatite (Lu-177 HA) particulates; first case report and image of Lu -177 HA in the elbow joint
  6. 226
    “…Purpose: To characterise efficacy and safety of (177)Lu-DOTATOC as agent for peptide receptor radiotherapy (PRRT) of advanced neuroendocrine tumours (NET). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
  7. 227
    “…INTRODUCTION: The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) receiving [(177)Lu]Lu-PSMA-617 therapy has been the subject of controversy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
  8. 228
    “…In n = 29 mCRPC patients with worsening disease after a median of four cycles of [(177)Lu]Lu-PSMA-617 RLT, combined [(18)F]FDG and [(68)Ga]Ga-PSMA-11 PET imaging was performed to detect [(18)F]FDG-avid lesions with low or no PSMA expression (mismatch lesions). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Value of Combined PET Imaging with [(18)F]FDG and [(68)Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [(177)Lu]Lu-PSMA-617 RLT
  9. 229
    “…METHODS: We compared the efficacy, safety, and costs of [177Lu]Lu-DOTA-TATE, everolimus (both originator and generic products), and sunitinib in patients with advanced GEP-NETs (NET G1 and G2) that had progressed following treatment with somatostatin analogs (SSAs). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    [(177)Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective
  10. 230
    “…Earlier studies have mostly identified pre-therapeutic clinical and laboratory parameters for the prediction of treatment response to [(177)Lu]Lu-PSMA-617 in metastatic castration resistant prostate cancer patients (mCRPC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Baseline Imaging Derived Predictive Factors of Response Following [(177)Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis
  11. 231
    “…RLT was offered for 32 patients with the MONO scheme (five cycles of [(177)Lu]Lu-DOTATOC) and for 24 with the DUO scheme (three cycles of [(177)Lu]Lu-DOTATOC alternated with two cycles of [(90)Y]Y-DOTATOC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Glucose Metabolism Modification Induced by Radioligand Therapy with [(177)Lu]Lu/[(90)Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
  12. 232
    por Lu, Cary
    Publicado 1994
    Libro
    Manual de Macintosh
  13. 233
    por Assadi, Majid, Ahmadzadehfar, Hojjat
    Publicado 2019
    “…This study presents a case of RrDTC who was treated with (177)Lu-DOTATATE and (177)Lu-PSMA, presumably as a first report in this regard.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    (177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
  14. 234
    “…(177)Lu-PSMA-617 is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    (177)Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial
  15. 235
    “…In this study, we investigated co-medication with enzalutamide as a potential re-sensitizer for PSMA-RLT in patients with imminent treatment failure on standard (177)Lu-based PSMA-RLT. Ten mCRPC patients who exhibited an insufficient response to conventional [(177)Lu]Lu-PSMA-617 RLT received oral medication of enzalutamide 160 mg/d as an adjunct to continued PSMA-RLT. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [(177)Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure—Preliminary Evidence of Pilot Experience
  16. 236
    “…PURPOSE: Targeted radionuclide therapy (TRT) with [(131)I]MIBG and [(177)Lu]Lu-DOTA-TATE is an alternative treatment to the classic schemes in slow progressive metastatic/inoperable paraganglioma (PGL) and pheochromocytoma (PHEO). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Response to targeted radionuclide therapy with [(131)I]MIBG AND [(177)Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review
  17. 237
    Enlace del recurso
    Measurement of the partial ($n,\gamma$) cross section to $^{176}Lu^{m}$ at s-process temperatures
  18. 238
    Enlace del recurso
    175Lu(n,n'γ) gamma-ray production cross section measurements
  19. 239
    por Berrou, Jean-Paul
    Publicado 1991
    “…Ce qu'il faut savoir pour bien rédiger ses écrits professionnels au travers d'une démarche méthodique pour bien organiser sa pensée en vue d'écrire efficacement, de conseils et de techniques pour être compris à coup sûr et être lu jusqu'au bout avec intérêt. Agrémenté de nombreux exemples concrets.…”
    Enlace del recurso
    Bien écrire en affaires: savoir rédiger pour être lu et convaincre
  20. 240
    por Korzhik, M V, Lecoq, P
    Publicado 2005
    Enlace del recurso
    Enlace del recurso
    Physics of scintillation in REA1O$_{3}:Ce^{3+}$ (RE=Y, Lu)
Herramientas de búsqueda: RSS